Dermira, Inc. (NASDAQ:DERM) is among the top stocks that may remain in focus today as the company shares are trading 4.71% or 0.47 points lower from last closing price of $9.97, reaching $9.5 at last check. Any clue why there is so much of action in the DERM stock? The share price has dropped in 3 of the last 5 days and is up 44.28% over the past week. It will be exciting to see whether the stock manages to continue decreasing or take a minor break for the next few days. The move came on weak volume too with far less shares changing hands than in a normal session. Trading activity as of this writing weakened by -623,857 shares, and in total 217243 shares valued at $2.064 million were seen changing hands compared with 841100 shares valued at $8.386 million recorded at the previous session. You should take into consideration that a falling volume on lower prices shows the bearish trend but this is an early indication which means that the DERM stock is near its bottom.
Dermira, Inc. (DERM) shares have notched a 3-month gain of about 44.28%, but has still advanced 38.66% year to date. By comparison, the stock added 0.2% over the past 12 months, while it slipped -4.68% over the 1 month. The company’s market cap is around $498.5M, with its short interest ratio standing at 2.56%.
In the current trading session for DERM, the stock witnessed two major price actions, it rose to a high of $9.96 and was down as much as $9.35 at one point. The high recorded is very low when compared to their 52-week high which is $6. The 52-week high is now at -38.79 distance from current price. Their recent low of $15.48 represents a 57.94% recovery. This data is quite important for investors who look to benefit from the recent rise of the company’s stock. The price target currently for DERM is $22.88, this is above the recent high that the stock attained. Taking a look at the overall sentimental views of financial analysts, the trading pattern of this stock recently is very clear.
The stock of Dermira, Inc. earned $-5.34 per share in the trailing 12 months and has a P/E ratio of -1.78. You can compare it with that of similar companies in its industry to get a sense of whether the stock you’re looking to purchase is overvalued or undervalued. Its current price to earnings ratio is lower than the ones recorded by the industry which is 69.3 and lower compared to the sector’s average of 32.55. When the P/E ratio is low let’s say below 1.0, then the stock price is considered a good value. DERM also has P/S multiple of 10.67. This is smaller versus the 12 month P/S ratios of other companies in the same indutry. The peer average price to sales ratio is 49.5x.
The company recorded an interesting insider sale transaction by the Insider on Apr 08, 2019. A Securities and Exchanges Commission filings show that Eugene A Bauer sold a total of 35,000 DERM shares that day for a sum of around $525,000. The filings show that the insider now retains 43,900 shares, currently worth $417,050. Dermira, Inc. (DERM) insiders have acquired no shares in the stock within the past three months. The total insider sales reported to the SEC in that time frame amounted to 80,531 shares. In total, individual insiders traded 80,531 shares in the business, which makes up 53.722% of 149,902 shares that were traded over a year. In the past 12 months, insiders have purchased 49,805 shares while the seller parted with 100,097 shares.
DERM‘s last price was down -6.02% as compared to the average trading price of 50 days recorded at $10.11 while enlarging the period to 200 trading days, the average closing price was $10.96. At present, there are 50 million in the total number of common shares owned by the public and among those 50 million shares have been available to trade. The percentage of shares being held by the company management was 0.4% while institutions stake was 80.11%. The company has generated negative returns on equity over the last 12 months (-391.8%). It managed to keep its gross profit margin at 95.3% over the past 12 months.
When assessing the full upside of the DERM stock, there is another set of technicals that should be looked into and considered. Its -3.35% decline from moving average of $9.83 has brought about a negative sentiment when calculated over the last 20 days. The market has allocated a beta of 1.39 to the stock. With the beta been greater than one, this implies that the company shares are theoretically more volatile than the market, something that the traders definitely are keeping an eye on.
Most of the analysts surveyed by Thomson/First Call think quite highly of Dermira, Inc. — 8 analysts rate the stock as a buy with another 0 rating it strong buy. There are 1 analysts who maintain a hold rating for the stock, with 0 giving it a sell rating. Analysts arrived at a 12-month price target of $18.7138 on shares of Dermira, Inc. (NASDAQ:DERM), which corresponds to 97.40% upside potential than its current market price of $9.5 and implies potential despite the recent drop in the price. However, their current target price has fallen from $19.0888 a month ago and is up handily from the consensus target of $15.1014 a quarter ago.
In the last five years, the EPS of the company has been roughly -39.3%. Though the percentage looks disappointing, extra headwinds are emerging as looking out over a next 5-year period, with analysts estimating that their earnings will decrease annually by 0%. The revenue of the company has retreated at an average annualized rate of about 0 over the last five years. The company recently recorded an increase of 733.3%, but this figure is rather attractive.
Let’s briefly check the hedge fund interest towards DERM stock. GYL Financial Synergies LLC added position in the company after it grew 50% or 14,179 shares of its common stock. The hedge fund now owns 21,268 shares worth $202,046, SEC documents show. Metropolitan Life Insurance Co NY cut assets in the stock as 14467.57 shares have been sold, reducing its stake by -26% to 10,706 shares which are currently valued at $101,707. In addition, Jane Street Group LLC recently reported that it now owns 39,493 shares making a total of $375,184 based on the recent price. This refelects a change of 40% in their ownership.